{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=1%2F2+maintenance+fluids", "query": { "intervention": "1/2 maintenance fluids" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 94, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=1%2F2+maintenance+fluids&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T03:23:39.627Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02697292", "title": "IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Autoimmune Epilepsy" ], "interventions": [ { "name": "Intravenous Immunoglobulin", "type": "DRUG" }, { "name": "Placebos", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 17, "start_date": "2016-02", "completion_date": "2018-12-03", "has_results": true, "last_update_posted_date": "2019-12-30", "last_synced_at": "2026-09-10T03:23:39.627Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02697292" }, { "nct_id": "NCT02437890", "title": "A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "ALX-0061", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Ablynx, a Sanofi company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 312, "start_date": "2015-07", "completion_date": "2018-01", "has_results": true, "last_update_posted_date": "2019-02-26", "last_synced_at": "2026-09-10T03:23:39.627Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Artesia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02437890" }, { "nct_id": "NCT07167693", "title": "Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diabetes (DM)", "Diabetic Ketoacidosis", "Ketosis Prone Diabetes", "Hyperglycaemia (Diabetic)" ], "interventions": [ { "name": "Arginine hydrochloride", "type": "DRUG" }, { "name": "Sodium Chloride 0.9%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David K Carroll", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-12-19", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-09-10T03:23:39.627Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07167693" }, { "nct_id": "NCT00023244", "title": "Steroid Withdrawal in Pediatric Kidney Transplant Recipients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "End-Stage Renal Disease" ], "interventions": [ { "name": "Basiliximab", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Bactrim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "20 Years", "sex": "ALL", "summary": "1 Day to 20 Years" }, "enrollment_count": 274, "start_date": "2001-01", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2016-10-21", "last_synced_at": "2026-09-10T03:23:39.627Z", "location_count": 18, "location_summary": "Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023244" }, { "nct_id": "NCT03905525", "title": "Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sjögren Syndrome" ], "interventions": [ { "name": "CFZ533", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 273, "start_date": "2019-10-01", "completion_date": "2023-06-06", "has_results": true, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-09-10T03:23:39.627Z", "location_count": 8, "location_summary": "Suwanee, Georgia • Indianapolis, Indiana • Baton Rouge, Louisiana + 5 more", "locations": [ { "city": "Suwanee", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03905525" }, { "nct_id": "NCT04275479", "title": "Diabetes/ Endocrine Surveillance in SDS", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Shwachman-Diamond Syndrome" ], "interventions": [ { "name": "Oral Glucose Tolerance Test", "type": "DIAGNOSTIC_TEST" }, { "name": "Modified Oral Glucose Tolerance Test", "type": "OTHER" }, { "name": "Modified Mixed Meal Tolerance Test", "type": "OTHER" }, { "name": "Continuous Glucose Monitor", "type": "DEVICE" }, { "name": "Food Diary", "type": "OTHER" }, { "name": "Medical History Questionnaires", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "OTHER", "DEVICE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 11, "start_date": "2020-01-10", "completion_date": "2022-12-30", "has_results": false, "last_update_posted_date": "2024-08-19", "last_synced_at": "2026-09-10T03:23:39.627Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04275479" }, { "nct_id": "NCT06146634", "title": "Washington State Driving Intervention Research Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Driving Behavior" ], "interventions": [ { "name": "Hazard Perception Training", "type": "BEHAVIORAL" }, { "name": "Vehicle Maintenance Training", "type": "BEHAVIORAL" }, { "name": "Attention Maintenance Training", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Johns Hopkins Bloomberg School of Public Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 8000, "start_date": "2024-07-15", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-09-10T03:23:39.627Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06146634" }, { "nct_id": "NCT00787176", "title": "The Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pregnancy", "Labor Pain" ], "interventions": [ { "name": "Group A Intravenous bolus of 1000 ml lactated ringers solution", "type": "DRUG" }, { "name": "Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1/2 current rate", "type": "DRUG" }, { "name": "Group C 125 mL/hr of lactated ringers", "type": "DRUG" }, { "name": "Group D 125 mL/hr lactated ringers oxytocin decreased to 1/2 current rate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "FEMALE", "summary": "18 Years to 60 Years · Female only" }, "enrollment_count": 251, "start_date": "2007-09", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2022-01-13", "last_synced_at": "2026-09-10T03:23:39.627Z", "location_count": 2, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00787176" }, { "nct_id": "NCT03909178", "title": "Arthroscopic Labral Repair Versus Physical Therapy for Tears of the Acetabular Labrum", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acetabular Labrum Tear", "Femoro Acetabular Impingement", "Hip Arthroscopy", "Physical Therapy", "Osteoarthritis, Hip" ], "interventions": [ { "name": "Hip Arthroscopy Surgery with Acetabular Labral Repair (SPT group)", "type": "PROCEDURE" }, { "name": "Physical Therapy Focused on the Hip and Hemi-pelvis (PT group)", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2013-10-21", "completion_date": "2030-06", "has_results": true, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-09-10T03:23:39.627Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03909178" }, { "nct_id": "NCT03131648", "title": "Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Tralokinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LEO Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 802, "start_date": "2017-05-30", "completion_date": "2019-10-10", "has_results": true, "last_update_posted_date": "2025-03-11", "last_synced_at": "2026-09-10T03:23:39.627Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03131648" } ] }